Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cirrhosis II: Pathophysiology01:24

Cirrhosis II: Pathophysiology

Cirrhosis is a progressive chronic liver injury caused by prolonged inflammation, excessive fibrotic remodeling, and impaired regeneration. Over time, repeated hepatic insults disrupt the liver’s architecture and function, leading to reduced blood flow, impaired bile drainage, and diminished metabolic capacity.Pathophysiology of cirrhosisCirrhosis arises from three main responses to chronic liver damage: inflammation, immune activation, and hepatocyte death. These processes lead to structural...
Clot Retraction and Fibrinolysis01:16

Clot Retraction and Fibrinolysis

After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
Cirrhosis I: Introduction01:23

Cirrhosis I: Introduction

Cirrhosis is a chronic, irreversible liver disease characterized by the widespread replacement of healthy liver tissue with fibrotic scar tissue and the formation of regenerative nodules.Etiology of cirrhosisCirrhosis results from sustained liver injury that triggers progressive fibrosis and structural remodeling. The underlying causes are diverse, encompassing common and less frequent clinical conditions. Regardless of the origin, all causes lead to chronic inflammation, hepatocyte loss, and...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Neutrophil cathepsin G and risk of cardiovascular events in patients with diabetes mellitus.

Cardiovascular diabetology·2025
Same author

Tobacco Smoke Exposure and Oxidative Stress: The Role of Circulating Lipopolysaccharides in Heated and Conventional Products.

Antioxidants (Basel, Switzerland)·2025
Same author

Platelet Thromboxane B<sub>2</sub> overproduction associated with liver fibrosis severity in patients with MASLD.

Thrombosis research·2025
Same author

Frailty elements, direct oral anticoagulants and mortality risk in atrial fibrillation patients aged ≥ 80 or ≥ 90 years from the nationwide Italian START registry: a propensity score matching analysis.

GeroScience·2025
Same author

Oxidative Stress and Low-Grade Endotoxemia in Pediatric Acute-Onset Neuropsychiatric Syndrome (PANS) and Paediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcal Infections (PANDAS): Insights from a Cross-Sectional Study.

International journal of molecular sciences·2025
Same author

Gut Microbiota-Platelet Axis and Thrombosis in Advanced Chronic Liver Disease.

Thrombosis and haemostasis·2025

Related Experiment Video

Updated: Jun 26, 2026

Experimental and Imaging Techniques for Examining Fibrin Clot Structures in Normal and Diseased States
07:09

Experimental and Imaging Techniques for Examining Fibrin Clot Structures in Normal and Diseased States

Published on: April 1, 2015

Hyperfibrinolysis in liver disease.

Domenico Ferro1, Andrea Celestini2, Francesco Violi2

  • 1Department of Experimental Medicine, University of Rome, "La Sapienza", Rome, Italy; Institute of Clinical Medicine I, University of Rome, "La Sapienza", Policlinico Umberto I, 00181 Rome, Italy.

Clinics in Liver Disease
|January 20, 2009
PubMed
Summary
This summary is machine-generated.

Hyperfibrinolysis, a bleeding complication in cirrhosis, is debated due to testing limitations. It worsens liver disease severity and variceal bleeding in advanced cases.

More Related Videos

Mouse Model of Metabolic Dysfunction-Associated Steatotic Liver Disease with Fibrosis
06:26

Mouse Model of Metabolic Dysfunction-Associated Steatotic Liver Disease with Fibrosis

Published on: July 18, 2025

Bile Duct Ligation in Mice: Induction of Inflammatory Liver Injury and Fibrosis by Obstructive Cholestasis
08:56

Bile Duct Ligation in Mice: Induction of Inflammatory Liver Injury and Fibrosis by Obstructive Cholestasis

Published on: February 10, 2015

Related Experiment Videos

Last Updated: Jun 26, 2026

Experimental and Imaging Techniques for Examining Fibrin Clot Structures in Normal and Diseased States
07:09

Experimental and Imaging Techniques for Examining Fibrin Clot Structures in Normal and Diseased States

Published on: April 1, 2015

Mouse Model of Metabolic Dysfunction-Associated Steatotic Liver Disease with Fibrosis
06:26

Mouse Model of Metabolic Dysfunction-Associated Steatotic Liver Disease with Fibrosis

Published on: July 18, 2025

Bile Duct Ligation in Mice: Induction of Inflammatory Liver Injury and Fibrosis by Obstructive Cholestasis
08:56

Bile Duct Ligation in Mice: Induction of Inflammatory Liver Injury and Fibrosis by Obstructive Cholestasis

Published on: February 10, 2015

Area of Science:

  • Hepatology
  • Hematology
  • Clinical Pathology

Background:

  • The incidence and clinical significance of hyperfibrinolysis in cirrhosis remain debated.
  • Uncertainty stems from the lack of validated laboratory tests for evaluating hyperfibrinolysis.
  • Hyperfibrinolysis is recognized as a potential complication, particularly in moderate to severe liver failure.

Purpose of the Study:

  • To explore the role and diagnostic challenges of hyperfibrinolysis in liver cirrhosis.
  • To correlate hyperfibrinolysis with the severity of liver disease.
  • To understand the impact of hyperfibrinolysis on hemostasis and bleeding complications.

Main Methods:

  • Literature review on hyperfibrinolysis in cirrhosis.
  • Analysis of existing data on laboratory test limitations.
  • Correlation studies between fibrinolysis markers and liver disease severity.

Main Results:

  • Hyperfibrinolysis incidence in cirrhosis is uncertain due to diagnostic limitations.
  • A positive correlation exists between hyperfibrinolysis and liver disease severity.
  • Low-grade systemic fibrinolysis affects 30-46% of end-stage liver disease patients.
  • Accelerated intravascular coagulation and secondary hyperfibrinolysis are reported in liver failure.

Conclusions:

  • Hyperfibrinolysis complicates liver cirrhosis, especially with advanced liver failure.
  • It may impair primary hemostasis, worsening variceal bleeding and recurrence.
  • Further research is needed to establish reliable diagnostic tools for hyperfibrinolysis in cirrhosis.